Stoke Therapeutics, Inc. has named Ian Smith as its new Chief Executive Officer, succeeding his role as Interim CEO since March 2025. Arthur Tzianabos will return to his position as Chairman of the Board. Smith was chosen after a thorough search and is seen as the right fit to lead Stoke. The company is currently conducting a global Phase 3 trial for its lead candidate, zorevunersen, a potential treatment for Dravet syndrome. Stoke Therapeutics’ stock closed 2.98% higher at $25.56 on the Nasdaq.

Read more at Nasdaq MarketSite: Stoke Therapeutics Names Ian Smith As CEO; Phase 3 Trial Of Zorevunersen Underway